IL270781A - Treatment of depressive disorders - Google Patents
Treatment of depressive disordersInfo
- Publication number
- IL270781A IL270781A IL270781A IL27078119A IL270781A IL 270781 A IL270781 A IL 270781A IL 270781 A IL270781 A IL 270781A IL 27078119 A IL27078119 A IL 27078119A IL 270781 A IL270781 A IL 270781A
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- depressive disorders
- depressive
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762510481P | 2017-05-24 | 2017-05-24 | |
| US15/933,673 US20180338959A1 (en) | 2017-05-24 | 2018-03-23 | Treatment of depressive disorders |
| PCT/US2018/033848 WO2018217718A1 (en) | 2017-05-24 | 2018-05-22 | Treatment of depressive disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL270781A true IL270781A (en) | 2020-01-30 |
Family
ID=64395877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL270781A IL270781A (en) | 2017-05-24 | 2019-11-20 | Treatment of depressive disorders |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20180338959A1 (enExample) |
| EP (2) | EP3630065A4 (enExample) |
| JP (2) | JP2020520963A (enExample) |
| KR (1) | KR20200018485A (enExample) |
| CN (2) | CN110996910A (enExample) |
| AU (1) | AU2018272819A1 (enExample) |
| CA (1) | CA3064299A1 (enExample) |
| IL (1) | IL270781A (enExample) |
| MX (1) | MX393452B (enExample) |
| WO (1) | WO2018217718A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2017156103A1 (en) | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2019213286A1 (en) * | 2018-05-02 | 2019-11-07 | LifeMax Laboratories, Inc. | Extended release suspension formulation of lurasidone |
| BR112021009944A2 (pt) | 2018-11-21 | 2021-08-17 | Certego Therapeutics Inc. | gaboxadol para reduzir risco de suicídio e alívio rápido de depressão |
| AU2020223284A1 (en) | 2019-02-17 | 2021-09-16 | Neurawell Therapeutics | Compositions and methods for treatment of depression and other disorders |
| KR102085938B1 (ko) * | 2019-11-04 | 2020-03-06 | 한국메탈실리콘 주식회사 | 실리콘 복합체 제조방법 |
| JP2023526439A (ja) | 2020-05-20 | 2023-06-21 | セルテゴ セラピューティクス インコーポレイテッド | 精神障害の処置のための環重水素化ガボキサドールおよびその使用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK270378A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Isoxazolderivater |
| US4362731A (en) | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
| US4353910A (en) | 1981-11-27 | 1982-10-12 | Kefalas A/S | Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment |
| AR031473A1 (es) * | 2000-11-20 | 2003-09-24 | Lundbeck & Co As H | Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide |
| US20020165217A1 (en) * | 2001-05-01 | 2002-11-07 | Pfizer Inc. | Combination treatment for anxiety and depression |
| EP2145620A3 (en) * | 2003-06-25 | 2010-03-17 | H. Lundbeck A/S | Gaboxadol for treating depression and other affective disorders |
| CL2004001603A1 (es) * | 2003-06-25 | 2005-05-27 | Lundbeck & Co As H | Uso de gabaxadol para preparar un medicamento util para el tratamiento del dolor neuropatico. |
| US20050234093A1 (en) * | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
| AU2005229493A1 (en) | 2004-04-02 | 2005-10-13 | H. Lundbeck A/S | Treatment of impaired respiratory function with gaboxadol |
| US20090048288A1 (en) * | 2007-08-13 | 2009-02-19 | H. Lundbeck A/S | Method of treating stress-mediated depression |
| US10628156B2 (en) * | 2013-07-09 | 2020-04-21 | Texas Instruments Incorporated | Vector SIMD VLIW data path architecture |
| RS62006B1 (sr) * | 2014-06-06 | 2021-07-30 | Ovid Therapeutics Inc | Postupci pojačavanja tonične inhibicije i lečenja sekundarne nesanice |
| MX391708B (es) * | 2015-07-17 | 2025-03-21 | Ovid Therapeutics Inc | Metodos para tratar trastornos del desarrollo con gaboxadol. |
| WO2017027249A1 (en) * | 2015-08-11 | 2017-02-16 | Ovid Therapeutics Inc. | Methods of sedation and parenteral formulation for use during critical care treatment |
| CA3146737A1 (en) * | 2019-07-15 | 2021-01-21 | Ovid Therapeutics Inc. | Pharmaceutical formulations containing gaboxadol for therapeutic treatment |
-
2018
- 2018-03-23 US US15/933,673 patent/US20180338959A1/en not_active Abandoned
- 2018-05-22 AU AU2018272819A patent/AU2018272819A1/en not_active Abandoned
- 2018-05-22 KR KR1020197038042A patent/KR20200018485A/ko not_active Ceased
- 2018-05-22 JP JP2019564822A patent/JP2020520963A/ja active Pending
- 2018-05-22 CA CA3064299A patent/CA3064299A1/en active Pending
- 2018-05-22 EP EP18805653.5A patent/EP3630065A4/en not_active Withdrawn
- 2018-05-22 EP EP21195602.4A patent/EP3939587A1/en not_active Withdrawn
- 2018-05-22 MX MX2019014024A patent/MX393452B/es unknown
- 2018-05-22 CN CN201880048161.4A patent/CN110996910A/zh active Pending
- 2018-05-22 CN CN202210735249.1A patent/CN115105499A/zh active Pending
- 2018-05-22 WO PCT/US2018/033848 patent/WO2018217718A1/en not_active Ceased
- 2018-12-18 US US16/223,356 patent/US20190117633A1/en not_active Abandoned
-
2019
- 2019-11-20 IL IL270781A patent/IL270781A/en unknown
-
2020
- 2020-02-19 US US16/794,354 patent/US20200179351A1/en not_active Abandoned
-
2021
- 2021-08-18 US US17/405,525 patent/US20210379028A1/en not_active Abandoned
-
2023
- 2023-01-25 JP JP2023009149A patent/JP2023061957A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018272819A1 (en) | 2019-12-05 |
| CN115105499A (zh) | 2022-09-27 |
| CN110996910A (zh) | 2020-04-10 |
| EP3939587A1 (en) | 2022-01-19 |
| EP3630065A4 (en) | 2021-03-24 |
| US20190117633A1 (en) | 2019-04-25 |
| CA3064299A1 (en) | 2019-11-29 |
| US20200179351A1 (en) | 2020-06-11 |
| JP2023061957A (ja) | 2023-05-02 |
| MX2019014024A (es) | 2020-02-17 |
| US20180338959A1 (en) | 2018-11-29 |
| KR20200018485A (ko) | 2020-02-19 |
| US20210379028A1 (en) | 2021-12-09 |
| MX393452B (es) | 2025-03-24 |
| WO2018217718A1 (en) | 2018-11-29 |
| JP2020520963A (ja) | 2020-07-16 |
| EP3630065A1 (en) | 2020-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006746B (en) | Methods of treatment | |
| IL273693A (en) | Treatment of inflammatory disorders | |
| IL285151B1 (en) | Methods for the treatment of fgf21-related disorders | |
| IL270781A (en) | Treatment of depressive disorders | |
| IL259861A (en) | Methods and preparations for the treatment of disorders related to seizures | |
| GB201804514D0 (en) | Treatment of pyroptosis | |
| GB201608046D0 (en) | Treatment of complement-mediated disorders | |
| IL269604A (en) | Pentides for the treatment of autoimmune diseases | |
| ZA201705847B (en) | Treatment of pain | |
| GB201612043D0 (en) | Composition for treatment of disorders | |
| EP3258930A4 (en) | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders | |
| GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
| GB201804515D0 (en) | Treatment of necroptosis | |
| LT3458067T (lt) | Neurologinių sutrikimų gydymas | |
| IL270362B (en) | Glaucoma treatment | |
| SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
| PL3713572T3 (pl) | Leczenie tachykardii | |
| IL257935A (en) | Treatment of bone growth disorders | |
| GB201717629D0 (en) | Treatment of unipolar depressive disorder | |
| ZA202002910B (en) | Treatment of skin disorders | |
| GB201713760D0 (en) | Treatment of epilepsy | |
| GB201604359D0 (en) | Treatment of tissue disorders | |
| GB201714303D0 (en) | Treatment of neurodegenerative diseases | |
| GB201714311D0 (en) | Treatment of neurodegenerative diseases | |
| GB201602784D0 (en) | New treatment of CFTR-related disorders |